SCHEMBL649866

SCHEMBL649866

CC(=O)Nc1ncc(/C=C2\S/C(=N\c3ccc(O)c(C)c3C)NC2=O)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 1/20 0.45
MAPT P10636 8/20 0.41
NPSR1 Q6W5P4 5/20 0.41
RNASEL Q05823 1/20 0.40
MEN1 O00255 7/20 0.39
KMT2A Q03164 7/20 0.39
MAPK1 P28482 2/20 0.39
PTP4A3 O75365 1/20 0.39
LMNA P02545 2/20 0.39
PTPN11 Q06124 2/20 0.39
ALOX15 P16050 1/20 0.39
PTGS2 P35354 1/20 0.39
RECQL P46063 1/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 2/20 0.36
CFTR P13569 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651471 1.00 GRK6 (0.45) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL650949 0.92 GRK6 (0.48) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL650948 0.92 GRK6 (0.48) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL650934 0.87 MAPT (0.56) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL650933 0.87 MAPT (0.56) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL651180 0.87 MEN1 (0.43) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL651181 0.87 MEN1 (0.43) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL649588 0.86 MAPT (0.46) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL649589 0.86 MAPT (0.46) GRK6MAPTNPSR1RNASELMEN1
SCHEMBL652061 0.85 MAPT (0.56) GRK6MAPTNPSR1RNASELMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 GRK6 1322/4885MAPT 3657/4885NPSR1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.